Pluri is translating more than two decades of cell-technology, manufacturing and clinical experience into a focused commercial strategyRegenerative medicine and the U.S. market are central to this next phase, supported by ZEO, CellaV and PluriCDMOClinical progress, strategic partnerships and greater financial alignment provide multiple avenues to unlock value across Pluri’s asset base HAIFA, Israel, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq and TASE: PLUR) (“Pluri” or the “Company”) t
English-language call at 8:30 a.m. Eastern Time and Hebrew-language call at 11:00 a.m. Israel Time on Thursday, October 29, 2026HAIFA, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq and TASE: PLUR) (“Pluri” or the “Company”), a biotechnology company advancing cell-based solutions for health and longevity, will host an online investor conference via Zoom this coming Thursday, October 29, 2026, featuring Mr. Yaky Yanay, CEO and President of Pluri and Mr. Alejandro Weinstein, Chairman
Partnership combines Pluri’s proprietary cell technology and clinical-development experience with ZEO’s biologics manufacturing expertise, established physician network, and sales, marketing, and educational infrastructure Pluri and ZEO Scientifix Strategic Agreement Ian Bothwell, CEO of ZEO, Bob Smoley, Founder of ZEO, Yaky Yanay CEO of Pluri Established U.S. commercial platform: ZEO contributes biologics manufacturing, scientific expertise, an existing product portfolio, physician relationship
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
Detailed price information for Pluri Inc (PLUR-Q) from The Globe and Mail including charting and trades.
HAIFA, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri”), a biotechnology company, leveraging its proprietary three-dimensional ("3D") cell expansion platform across two principal business verticals: (i) Human Health & Longevity and (ii) FoodTech & Bio-Farming, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor, for the purchase and sale of 2,228,940 Common Shares (or Common Sha
This is the newest page. Registered accounts read further back.